Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Policy Research & Development Innovation

Takeda-BIRAC Alliance Deepens Big Pharma Support For Biotech Start-ups In India

Proposed National Pharmaceutical Policy To Further Agenda

  • Analysis

Executive Summary

Takeda’s alliance with BIRAC marks a deepening of big pharma’s support for India’s budding biotech innovation ecosystem. Takeda brings strengths in rare diseases and immunology to a table shared by others like Pfizer and Novartis. Meanwhile, the proposed National Pharmaceutical Policy is seen furthering innovation via public-private partnerships

Table

View full table

Related Content

Scrip
Pink Sheet
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Policy Research & Development Innovation
Latest Headlines

AstraZeneca And Daiichi Get Low

Pipeline Watch: Eighteen Approvals And Six Phase III Trial Updates

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

See All
UsernamePublicRestriction

Register

SC149498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By